Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Por:
Banerjee, S, Ottevanger, PB, Sarivalasis, A, Le Scodan, R, Montes, A, Kroep, JR, Marin, MR, Herraez, AC, Auvray-Kuentz, M, Westermann, AM, Lucas, B, Dangaj, D, Herrera, F, Wolfer, A, Coens, C, Vanlancker, MB, Kandalaft, L and Coukos, G
Publicada:
1 sep 2021
Ahead of Print:
1 sep 2021
Resumen:
Filiaciones:
Banerjee, S:
Royal Marsden Hosp NHS Fdn Trust, Gynaecol Dept, London, England
Ottevanger, PB:
Radboud Univ Nijmegen, Med Ctr, Med Oncol, Nijmegen, Netherlands
Sarivalasis, A:
CHUV Ctr Hosp Univ Vaudois, Oncol, Lausanne, Switzerland
Le Scodan, R:
Ctr Radiotherapie St Vincent, Oncol Radiotherapy, St Gregoire, France
Montes, A:
Guys & St Thomas NHS Fdn Trust, Med Oncol, London, England
Kroep, JR:
Leiden Univ Med Ctr LUMC, Med Oncol Dept, Leiden, Netherlands
:
Hosp Germans Trias Pujol, Catalan Inst Oncol ICO Badalona, Med Oncol Dept, Barcelona, Spain
Herraez, AC:
Hosp Clinico Univ San Carlos, Dept Med Oncol, Madrid, Spain
Auvray-Kuentz, M:
AP HP Hop Europeen Georges Pompidou, Oncol, Paris, France
Westermann, AM:
Amsterdam Univ Med Ctr UMC, Locatie Acad Med Ctr AMC, Med Oncol Dept, Amsterdam, Netherlands
Lucas, B:
CHU Brest Hop Morvan, Oncol, Brest, France
Dangaj, D:
Ludwig Inst Canc Res, Oncol, Lausanne Branch, Epalinges, Switzerland
Herrera, F:
CHUV Ctr Hosp Univ Vaudois, Immuno Oncol Dept, Lausanne, Switzerland
Wolfer, A:
CHUV Ctr Hosp Univ Vaudois, Oncol, Lausanne, Switzerland
Coens, C:
EORTC European Org Res & Treatment Canc, Statist, Brussels, Belgium
Vanlancker, MB:
EORTC AISB LIVZW European Org Res & Treatment, Med Dept, Brussels, Belgium
Kandalaft, L:
Ctr Hosp Univ Vaudois CHUV, Ctr Expt Therapeut, Dept Oncol, Lausanne, Switzerland
Coukos, G:
Ludwig Inst Canc Res, Oncol, Lausanne Branch, Epalinges, Switzerland
Bronze
|